Lu-177-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2029-06-01
Target enrollment:
Participant gender:
Summary
A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of
177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant
Prostate Cancer.